arrow
F

François Bertucci

Institut Paoli-Calmettes
H指数:95
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A deep-learning model based on histological images predicts survival and pathological response to neoadjuvant chemotherapy and chemoimmunotherapy in breast cancer

基于组织学图像的深度学习模型预测乳腺癌新辅助化疗和化疗免疫治疗后的生存期及病理反应

2026-11-030
OAAI
Multiscale modeling uncovers macrophage infiltration and TNF-α signaling networks for targeting in inflammatory breast cancer tumor emboli

多尺度建模揭示炎性乳腺癌肿瘤栓子中巨噬细胞浸润和TNF-α信号网络可作为治疗靶点

Breast
IF7.9
2026-08-010
PRE
MiT fusions, TSC1–TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa

MiT融合、TSC1–TSC2分化以及干细胞样程序揭示PEComa的不同起源和脆弱性

2026-06-230
OAAI
Characteristics and outcome of intra-abdominal desmoid-type fibromatosis

腹内型硬纤维瘤的特征和预后

2026-05-190
PRE
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025

2025年国际炎性乳腺癌研讨会的重要科学成果与展望

Cancer
IF5.1
2026-05-140
PRE
The spatial immune landscape predicts outcome and reveals the central role of tumor-associated macrophages in inflammatory breast cancer biology

空间免疫景观预测结果并揭示肿瘤相关巨噬细胞在炎性乳腺癌生物学中的核心作用

2026-01-050
OAAI
The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage

细胞外基质驱动鸟苷酸产生,并保护胰腺癌细胞免受奥沙利铂诱导的DNA损伤。

2025-12-120
OA
Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity

更正:Menin抑制可抑制去势抵抗性前列腺癌并增强化疗敏感性

2025-10-280
OAAI
Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”

“索拉非尼在局部晚期和转移性脊索瘤患者中的应用: 法国肉瘤组 (GSF/GETO) 的II期试验”

2025-10-150
PRE
The role of body mass index at diagnosis in patients with inflammatory breast cancer

炎性乳腺癌患者诊断时体重指数的作用

2025-10-120
OAAI
Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database

1773例非皮肤纤维肉瘤浅表肉瘤的结局:一项来自NETSARC数据库的法国肉瘤组(FSG)研究

2025-09-120
PRE
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer

靶向DDX5 mRNA的反义寡核苷酸作为对抗去势抵抗性前列腺癌的新型有前景的治疗方法

2025-09-110
PRE
Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry

临床表现、治疗管理及结局:11,132例脂肪肉瘤患者的流行病学研究(基于NETSARC+登记系统)

2025-07-310
PREAI
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial

接受伊马替尼治疗的晚期胃肠道间质瘤的二十年生存率:BFR14试验的探索性长期随访

2025-05-280
OAAI
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization

AXL通过调控免疫抑制性巨噬细胞极化促进炎性乳腺癌进展

2025-05-060
OA
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

瑞戈非尼作为一线多柔比星类化疗后的维持疗法在进展期非脂肪源性软组织肉瘤患者中的应用:一项双盲随机试验☆

2025-04-080
PRE